Tu Van Dao

Hanoi Medical University — VN

Medicine · Health Sciences

15h-index2.7kcitations82works22.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(14), Microgrid Control and Optimization(8), Liver Disease Diagnosis and Treatment(8), Smart Grid Energy Management(8), Lung Cancer Treatments and Mutations(7)

Publications81 total

Outcomes of 3D Endoscopic Mitral Valve Replacement Combined with Radiofrequency Ablation for Atrial Fibrillation
Tạp chí Phẫu thuật và Tim mạch và Lồng ngực Việt Nam·2025Open Access
Response to comments on “The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis”
Nutrition Metabolism and Cardiovascular Diseases·2025
P3.12.49 Clinical Significance of a Genomic Screening Platform of Non-Small Cell Lung Cancer in Asia-Pacific: LC-SCRUM-AP
Journal of Thoracic Oncology·2025
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie·2025
Subsequent anticancer therapy analysis of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Zeitschrift für Gastroenterologie·2025
The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis
Nutrition Metabolism and Cardiovascular Diseases·2025· 2 citedOpen Access
Study of the melting of FeSi interstitial alloy films by SMM
HPU2 Journal of Science Natural Sciences and Technology·2025Open Access
404: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY BASELINE LIVER FUNCTION FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB (T) PLUS DURVALUMAB (D) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology·2025
Su1751: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY TUMOR RESPONSE MEASURES FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology·2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Journal of Hepatology·2025· 68 cited
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study
Lung Cancer Targets and Therapy·2025· 1 citedOpen Access
Clinical application of the morse fall scale in assessing fall risk among parkinson’s disease patients at Bach Mai neurology center
Tạp chí thần kinh học Việt Nam·2025Open Access
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie·2025
149P Positivity rates of FGFR2 fusion gene or rearrangement and genetic profiling in Asian Cholangiocarcinoma
Annals of Oncology·2024
127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024· 4 citedOpen Access
MO62-5 Neoadjuvant chemotherapy treatment triple-negative breast cancer women younger than 45 years of age
Annals of Oncology·2024
947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024· 23 citedOpen Access
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Journal of Hepatology·2024· 27 citedOpen Access
Among Patients with Surgical Coronary Artery Disease who do not Receive Revascularisation, Higher Antianginal Usage Predicts Long-Term Mortality
Heart Lung and Circulation·2024Open Access
Impact of Clinical Presentation on Outcomes in Patients With Multivessel Coronary Artery Disease Managed Medically
Heart Lung and Circulation·2024Open Access
page 1 of 5Next →

Frequent Co-authors

George Lau(10), Lorenza Rimassa(9), Hideo Ishii(9), Yasuhiro Hayashi(9), Masatoshi Kudo(8), В. В. Бредер(8), Bruno Sangro(8), Ghassan K. Abou‐Alfa(7), Stephen L. Chan(7), Robin Kate Kelley(7), Junji Furuse(7), Wattana Sukeepaisarnjaroen(7), Vincent C. Tam(7), Alejandra Negro(7), Oanh Thi Bui(7), Yoon‐Koo Kang(6), Enrico N. De Toni(6), Alexandra Heurgué(6), Thuan V. Tran(6), Satheesh Chiradoni Thungappa(4)